In a regulatory filing, Intra-Cellular disclosed that its CEO Sharon Mates sold 33.9K shares of common stock on February 2nd in a total transaction size of $2.27M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular initiated with Outperform on Caplyta growth at Baird
- Intra-Cellular initiated with an Outperform at Baird
- Intra-Cellular price target raised to $82 from $74 at BofA
- Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Intra-Cellular rumor highlighted in Betaville blog